Downregulation of AnnexinA5 Gene Expression in Coronary In-Stent Restenosis – A Pilot Study

Abstract

Background and aims: In- stent restenosis (ISR) is the Achilles heel of angioplasty. AnnexinA5 as an anticoagulant has been shown have anti-inflammatory and anti-atherosclerotic effects. Here we aim to investigating the mRNA expression of AnnexinA5 in peripheral white blood cell of patients with in-stent restenosis. Methods Patients with the history of coronary stent implantation who candidate for re-angiography were entered the study and allocated into two groups according the results of re-angiography; in-stent restenosis (stenosis ≥ 50% in stent) and non-in-stent restenosis (stenosis < 50% in stent). Total RNA of WBC was extracted and cDNA was synthesized using commercial kits. AnnexinA5 expression was assessed with real time PCR and TaqMan probe and reported in relation with GAPDH as a housekeeping gene. Result AnnexinA5 expression was investigated in total 50 participants including 25 ISR and 25 non-ISR. Baseline characteristics including age, sex, smoking habits, hypertension, diabetes mellitus, dyslipidemia and stent in LAD were statistically the same in cases and controls. AnnexinA5 expression in ISR patients was 50% lower than controls. Conclusion AnnexinA5 is down-regulated in ISR and could be considered as a biomarker for predicting ISR and furthermore it could be used as prevention for ISR occurrence.